Black Diamond Therapeutics
BDTX
84 hedge funds and large institutions have $66.3M invested in Black Diamond Therapeutics in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 16 closing their positions.
126% more call options, than puts
Call options by funds: $156K | Put options by funds: $69K
3% less funds holding
Funds holding: 87 → 84 (-3)
12.73% less ownership
Funds ownership: 84.65% → 71.92% (-13%)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
35% less capital invested
Capital invested by funds: $103M → $66.3M (-$36.2M)
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.14M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.05M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$538K |
| 4 |
Morgan Stanley
New York
|
+$433K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$12.1M |
| 2 |
Renaissance Technologies
New York
|
-$1.73M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
-$1.08M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$776K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$648K |
BDTX Hedge Fund Activity: Q1 2025 in Review
84 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2025, worth a combined $66.3M — down 35% from $103M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BDTX and 13 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 18 added.
The largest buyer was Millennium Management, adding an estimated $1.14M. The largest seller was Bellevue Group, cutting an estimated $12.1M.
- 84 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2025, down from 87 in Q4 2024.
- Funds reported $66.3M of Black Diamond Therapeutics stock for Q1 2025, down 35% quarter-over-quarter.
- 13 funds opened new Black Diamond Therapeutics positions in Q1 2025 and 16 closed out, a net change of -3 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $1.14M added.
- The largest Black Diamond Therapeutics seller in Q1 2025 was Bellevue Group, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2025.